Cue Biopharma, Inc.

NASDAQ:CUE

Biotechnology

Healthcare
$14.10 +1.42%

+$0.38 today

Market cap
$102.43M
Beta
2.53
P/E (TTM)
-6.7
EPS (TTM)
-$4.06
52W Low $4.98High $41.42

Volume 0.21M

Average 0.74M

CUE Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Cue Biopharma, Inc.NASDAQ: CUE

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 4.81M shares rose 94.2% year over year, ahead of the +80.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 30.5% from the prior quarter. Over 3 fiscal years it compounded at +38.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +94.2% holds above the trailing-twelve-month pace of +80.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
4.81M+30.5% QoQ
Last fiscal yearDec 2025
3.16M+68.2% YoY
LTMMar 2026
3.76M+80.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+94.2%——
1 year+68.2%——
3-year CAGR+38.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
3.16M USD
Year-over-year change
+68.2%
4-year CAGR
+31.9%

Weighted Avg Shares (Diluted) vs competitors

How CUE compares with its peers on the latest reported figures

  • CUE's LTM Mar 2026 weighted avg shares (diluted) of 3.76M shares is the 6th highest of the 7 companies compared; the peer median is 27.2M shares.
  • Its year-over-year change of +80.5% is the 3rd highest of 7, against a peer median of +33.1%.
  • Over three fiscal years its annual growth of +38.5% compares with a peer median of +11.1%.
CUE Competitors Peer median
Weighted Avg Shares (Diluted) for CUE and competitors
Company Period LTM YoY 3-year CAGR
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
EQEquillium, Inc.LTM Mar 202664.9M +81.6%+39.7%
OTLKOutlook Therapeutics, Inc.LTM Mar 202628.35M +14.4%+33.9%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202626.06M +115.3%-31.2%
COEPCoeptis Therapeutics, Inc.LTM Mar 20264.68M -77.3%-33.3%
CUECue Biopharma, Inc.LTM Mar 20263.76M +80.5%+38.5%
SPRBSpruce Biosciences, Inc.LTM Mar 2026827.01K +51.8%+7.8%
Peer median (excluding CUE) 27.2M+33.1%+11.1%

Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.94M1.25M5.49M9.29M27.47M
Cost of Revenue(1.78M)038.1M00
Gross Profit16.72M1.25M(32.61M)9.29M27.47M
Gross Margin111.9%100.0%-593.9%100.0%100.0%
Research & Development41.35M38.58M40.8M36.3M37.74M
Selling, General & Admin17.31M16.17M16.68M14.59M16.24M
Operating Expenses60.43M54.47M19.54M50.79M53.99M
Depreciation & Amortization(1.78M)1.81M3.44M2.35M3.48M
EBITDA(45.44M)(50.49M)(46.05M)(37.53M)(22.27M)
EBITDA Margin-304.1%-4055.5%-838.8%-404.1%-81.1%
Operating Income(43.71M)(53.23M)(52.15M)(41.5M)(26.52M)
Operating Margin-292.6%-4275.1%-949.9%-446.9%-96.6%
Interest Income45.9K928.24K2.66M1.62M807K
Interest Expense0713.82K1.25M796K357K
Other Income / Expenses45.9K215K1.42M826K419K
Income Before Tax(43.67M)(53.01M)(50.73M)(40.67M)(26.1M)
Pre-Tax Margin-292.3%-4257.8%-924.1%-438.0%-95.0%
Income Tax Expense495K000500K
Net Income(44.16M)(53.01M)(50.73M)(40.67M)(26.6M)
Net Margin-295.6%-4257.8%-924.1%-438.0%-96.9%
EPS (Basic)(42.30)(44.70)(33.30)(21.60)(8.40)
EPS (Diluted)(42.30)(44.70)(33.30)(21.60)(8.40)
Weighted Avg Shares1.04M1.19M1.53M1.88M3.16M
Weighted Avg Shares (Diluted)1.04M1.19M1.53M1.88M3.16M

Cue Biopharma, Inc.

NASDAQ:CUE

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.